Mostrar el registro sencillo del ítem
Advances in the Development of SARS-CoV-2 Mpro Inhibitors
dc.contributor.author | Agost Beltrán, Laura | |
dc.contributor.author | de la hoz rodriguez, Sergio | |
dc.contributor.author | Bou Iserte, Lledó | |
dc.contributor.author | Rodríguez, Santiago | |
dc.contributor.author | Fernández de la Pradilla Ibáñez, Adrián | |
dc.contributor.author | González, Florenci | |
dc.date.accessioned | 2022-09-28T13:19:14Z | |
dc.date.available | 2022-09-28T13:19:14Z | |
dc.date.issued | 2022-04-14 | |
dc.identifier.citation | Agost-Beltrán, L.; de la Hoz-Rodríguez, S.; Bou-Iserte, L.; Rodríguez, S.; Fernández-de-la-Pradilla, A.; González, F.V. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Molecules 2022, 27, 2523. https://doi.org/10.3390/molecules 27082523 | ca_CA |
dc.identifier.issn | 1420-3049 | |
dc.identifier.uri | http://hdl.handle.net/10234/199927 | |
dc.description.abstract | Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs. | ca_CA |
dc.format.extent | 15 p. | ca_CA |
dc.format.mimetype | application/pdf | ca_CA |
dc.language.iso | eng | ca_CA |
dc.publisher | MDPI | ca_CA |
dc.relation | SomUJIContraCovid | ca_CA |
dc.relation.isPartOf | Molecules, Vol. 27, Iss. 8 (April-2 2022) | ca_CA |
dc.rights | Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | ca_CA |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | ca_CA |
dc.subject | COVID-19 | ca_CA |
dc.subject | main protease | ca_CA |
dc.subject | Mpro | ca_CA |
dc.subject | inhibitors | ca_CA |
dc.title | Advances in the Development of SARS-CoV-2 Mpro Inhibitors | ca_CA |
dc.type | info:eu-repo/semantics/article | ca_CA |
dc.identifier.doi | https://doi.org/10.3390/molecules27082523 | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca_CA |
dc.type.version | info:eu-repo/semantics/publishedVersion | ca_CA |
project.funder.name | Universitat Jaume I | ca_CA |
project.funder.name | Ministerio de Universidades | ca_CA |
oaire.awardNumber | UJI‐2021-71 | ca_CA |
oaire.awardNumber | FPU19/04913 | ca_CA |
oaire.awardNumber | FPU17/06209 | ca_CA |
oaire.awardNumber | FPU20/03516 | ca_CA |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
QFA_Articles [819]
Articles de publicacions periòdiques -
QUIO_Articles [695]
Articles de publicacions periòdiques
Excepto si se señala otra cosa, la licencia del ítem se describe como: Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).